Exousia’s candidate for malignant glioma gains US orphan drug status

Oct. 29, 2025

Exousia Pro Inc.’s subsidiary, Exousia AI, has received orphan drug designation from the FDA for its exosome-based treatment for malignant glioma.

BioWorld Science Regulatory Cancer FDA Orphan drug

Today's news in brief

BioWorld

BioWorld briefs for Dec. 5, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 4, 2025.

Illustration of chromosome unraveling down to the DNA

First phase of synthetic human genome project successfully completes

BioWorld

The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

Laigo raises €11.5M seed money for targeted protein degradation

BioWorld Science

Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...